| Year |
Citation |
Score |
| 2023 |
Lampe JB, Desai PP, Tripathi AK, Sabnis NA, Chen Z, Ranjan AP, Vishwanatha JK. Cabazitaxel-Loaded Nanoparticles Reduce the Invasiveness in Metastatic Prostate Cancer Cells: Beyond the Classical Taxane Function. Pharmaceutics. 15. PMID 36839985 DOI: 10.3390/pharmaceutics15020662 |
0.331 |
|
| 2020 |
Thyagarajan S, Zhang Y, Thapa S, Allen MS, Phillips N, Chaudhary P, Kashyap MV, Vishwanatha JK. Comparative analysis of racial differences in breast tumor microbiome. Scientific Reports. 10: 14116. PMID 32839514 DOI: 10.1038/S41598-020-71102-X |
0.348 |
|
| 2020 |
Hurtado M, Prokai L, Sankpal UT, Levesque B, Maram R, Chhabra J, Brown DT, Gurung RK, Holder AA, Vishwanatha JK, Basha R. Next generation sequencing and functional pathway analysis to understand the mechanism of action of copper-tolfenamic acid against pancreatic cancer cells. Process Biochemistry (Barking, London, England). 89: 155-164. PMID 32719579 DOI: 10.1016/J.Procbio.2019.10.022 |
0.41 |
|
| 2020 |
Chaudhary P, Gibbs LD, Maji S, Lewis CM, Suzuki S, Vishwanatha JK. Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis. Breast Cancer Research : Bcr. 22: 31. PMID 32293512 DOI: 10.1186/S13058-020-01268-9 |
0.343 |
|
| 2020 |
Chaudhary P, Gibbs LD, Maji S, Lewis CM, Suzuki S, Vishwanatha JK. Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis. Breast Cancer Research : Bcr. 22: 11. PMID 31992335 DOI: 10.1186/S13058-020-1251-8 |
0.377 |
|
| 2020 |
Thyagarajan S, Zhang Y, Thapa S, Allen MS, Phillips N, Vishwanatha JK. Abstract B26: Comparative analysis of breast tumor microbiome in Black non-Hispanic (BNH) and White non-Hispanic (WNH) women Cancer Research. 80. DOI: 10.1158/1538-7445.Mvc2020-B26 |
0.344 |
|
| 2019 |
Patel K, Siraj S, Smith C, Nair M, Vishwanatha JK, Basha R. Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy. Critical Reviews in Oncogenesis. 24: 105-118. PMID 31679206 DOI: 10.1615/Critrevoncog.2019031417 |
0.388 |
|
| 2019 |
Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, Basha R. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Medicine. PMID 31560828 DOI: 10.1002/Cam4.2560 |
0.309 |
|
| 2019 |
Kumar P, Treuren TV, Ranjan A, Chaudhary P, Vishwanatha JK. In vivo imaging and biodistribution of near infrared dye loaded brain-metastatic-breast-cancer-cell-membrane coated polymeric nanoparticles. Nanotechnology. PMID 30865940 DOI: 10.1088/1361-6528/Ab0F46 |
0.386 |
|
| 2019 |
Gdowski A, Ranjan A, Lampe J, Lin V, Wang Y, Mukerjee A, Vishwanatha J. Bioinformatic inspired nanoparticles engineered for enhanced delivery to the bone. Journal of Clinical Oncology. 37: e14637-e14637. DOI: 10.1200/Jco.2019.37.15_Suppl.E14637 |
0.399 |
|
| 2019 |
Hurtado M, Prokai L, Sankpal UT, Levesque B, Maram R, Chhabra J, Brown DT, Gurung RK, Holder AA, Vishwanatha J, Basha R. Abstract 4811: Functional pathway analysis in pancreatic cancer cells treated with a novel anti-cancer agent, copper-tolfenamic acid Cancer Research. 79: 4811-4811. DOI: 10.1158/1538-7445.Am2019-4811 |
0.402 |
|
| 2018 |
Hurtado M, Sankpal UT, Kaba A, Mahammad S, Chhabra J, Brown DT, Gurung RK, Holder AA, Vishwanatha JK, Basha R. Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 51: 1894-1907. PMID 30504717 DOI: 10.1159/000495715 |
0.38 |
|
| 2018 |
Gibbs LD, Chaudhary P, Mansheim K, Hare RJ, Mantsch RA, Vishwanatha JK. ANXA2 expression in African American triple-negative breast cancer patients. Breast Cancer Research and Treatment. PMID 30478786 DOI: 10.1007/S10549-018-5030-5 |
0.338 |
|
| 2018 |
Van Treuren T, Vishwanatha JK. CRISPR deletion of MIEN1 in breast cancer cells. Plos One. 13: e0204976. PMID 30286132 DOI: 10.1371/Journal.Pone.0204976 |
0.436 |
|
| 2018 |
Marrufo AM, Mathew SO, Chaudhary P, Malaer JD, Vishwanatha JK, Mathew PA. Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells. American Journal of Cancer Research. 8: 1050-1063. PMID 30034942 |
0.307 |
|
| 2018 |
Hurtado M, Sankpal UT, Ranjan A, Maram R, Vishwanatha JK, Nagaraju GP, El-Rayes BF, Basha R. Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. Critical Reviews in Oncology/Hematology. 126: 201-207. PMID 29759562 DOI: 10.1016/J.Critrevonc.2018.03.016 |
0.372 |
|
| 2018 |
Desai PP, Lampe JB, Bakre SA, Basha RM, Jones HP, Vishwanatha JK. Evidence-based approaches to reduce cancer health disparities: Discover, develop, deliver, and disseminate. Journal of Carcinogenesis. 17: 1. PMID 29643743 DOI: 10.4103/Jcar.Jcar_13_17 |
0.322 |
|
| 2018 |
Gibbs LD, Vishwanatha JK. Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer. Oncotarget. 9: 2697-2704. PMID 29416802 DOI: 10.18632/Oncotarget.23627 |
0.367 |
|
| 2018 |
Gdowski A, Ranjan A, Sarker M, Vishwanatha J. Abstract B51: Targeted nanoparticle approach to treating metastatic prostate cancer Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Tcm17-B51 |
0.378 |
|
| 2017 |
Castañeda-Gill JM, Ranjan AP, Vishwanatha JK. Development and Characterization of Methylene Blue Oleate Salt-Loaded Polymeric Nanoparticles and their Potential Application as a Treatment for Glioblastoma. Journal of Nanomedicine & Nanotechnology. 8. PMID 29034126 DOI: 10.4172/2157-7439.1000449 |
0.344 |
|
| 2017 |
Gdowski AS, Ranjan A, Sarker MR, Vishwanatha JK. Bone targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (London, England). PMID 28805551 DOI: 10.2217/Nnm-2017-0190 |
0.325 |
|
| 2017 |
Gibbs LD, Chaudhary P, Vishwanatha JK. Abstract B03: Racial Variation in Annexin A2 (AnxA2) Gene Expression and Poor Outcome in Triple-Negative Breast Cancer Cancer Epidemiology, Biomarkers & Prevention. 26. DOI: 10.1158/1538-7755.Disp16-B03 |
0.381 |
|
| 2017 |
Chaudhary P, Kpetemey M, Treuren TV, Vishwanatha JK. Abstract 5812: MIEN1 promotes breast cancer cell migration and invasion by regulating cytoskeletal dynamics via focal adhesion kinase and N-WASP Cancer Research. 77: 5812-5812. DOI: 10.1158/1538-7445.Am2017-5812 |
0.376 |
|
| 2017 |
Gogoi RP, Castañeda-Gill JM, Metpally RP, Krishnamurthy SB, Vishwanatha JK, Carey DJ, Nash JD, Dasari VR. Abstract 117: Anti-proliferative and cytotoxic effects of verteporfin in endometrial cancer cells Cancer Research. 77: 117-117. DOI: 10.1158/1538-7445.Am2017-117 |
0.407 |
|
| 2017 |
Hurtado M, Sankpal U, Kaba A, Mahammad S, Holder A, Vishwanatha J, Basha R. Abstract 10: A small molecule derivative effectively inhibits proliferation of pancreatic cancer cells by targeting Sp1 and survivin Cancer Research. 77: 10-10. DOI: 10.1158/1538-7445.Am2017-10 |
0.382 |
|
| 2016 |
Mukerjee A, Ranjan AP, Vishwanatha JK. Targeted Nanocurcumin Therapy Using Annexin A2 Anitbody Improves Tumor Accumulation and Therapeutic Efficacy Against Highly Metastatic Breast Cancer. Journal of Biomedical Nanotechnology. 12: 1374-92. PMID 29336533 DOI: 10.1166/Jbn.2016.2240 |
0.469 |
|
| 2016 |
Maji S, Chaudhary P, Akopova I, Nguyen PM, Hare RJ, Gryczynski I, Vishwanatha JK. Exosomal Annexin A2 Promotes Angiogenesis and Breast Cancer Metastasis. Molecular Cancer Research : McR. PMID 27760843 DOI: 10.1158/1541-7786.Mcr-16-0163 |
0.435 |
|
| 2016 |
Mathew SO, Chaudhary P, Powers SB, Vishwanatha JK, Mathew PA. Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction. Oncotarget. PMID 27626681 DOI: 10.18632/Oncotarget.11896 |
0.42 |
|
| 2016 |
Rajendiran S, Gibbs LD, Van Treuren T, Klinkebiel DL, Vishwanatha JK. MIEN1 is tightly regulated by SINE Alu methylation in its promoter. Oncotarget. PMID 27589566 DOI: 10.18632/Oncotarget.11675 |
0.377 |
|
| 2016 |
Sankpal UT, Ingersoll SB, Ahmad S, Holloway RW, Bhat VB, Simecka JW, Daniel L, Kariali E, Vishwanatha JK, Basha R. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. PMID 27581819 DOI: 10.1007/S13277-016-5290-9 |
0.392 |
|
| 2016 |
Kpetemey M, Chaudhary P, Van Treuren T, Vishwanatha JK. MIEN1 drives breast tumor cell migration by regulating cytoskeletal-focal adhesion dynamics. Oncotarget. PMID 27462783 DOI: 10.18632/Oncotarget.10798 |
0.386 |
|
| 2016 |
Ranjan AP, Mukerjee A, Gdowski A, Helson L, Bouchard A, Majeed M, Vishwanatha JK. Curcumin-ER Prolonged Subcutaneous Delivery for the Treatment of Non-Small Cell Lung Cancer. Journal of Biomedical Nanotechnology. 12: 679-88. PMID 27301194 DOI: 10.1166/Jbn.2016.2207 |
0.404 |
|
| 2016 |
Basha R, Connelly SF, Sankpal UT, Nagaraju GP, Patel H, Vishwanatha JK, Shelake S, Tabor-Simecka L, Shoji M, Simecka JW, El-Rayes B. Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution. The Journal of Nutritional Biochemistry. 31: 77-87. PMID 27133426 DOI: 10.1016/J.Jnutbio.2016.01.003 |
0.361 |
|
| 2016 |
Castañeda-Gill JM, Vishwanatha JK. Antiangiogenic mechanisms and factors in breast cancer treatment. Journal of Carcinogenesis. 15: 1. PMID 27013929 DOI: 10.4103/1477-3163.176223 |
0.358 |
|
| 2016 |
Kokate RA, Chaudhary P, Sun X, Thamake SI, Maji S, Chib R, Vishwanatha JK, Jones HP. Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy. Nanomedicine (London, England). PMID 26892440 DOI: 10.2217/Nnm.15.213 |
0.736 |
|
| 2016 |
Shetty P, Bargale A, Patil BR, Mohan R, Dinesh US, Vishwanatha JK, Gai PB, Patil VS, Amsavardani TS. Cell surface interaction of annexin A2 and galectin-3 modulates epidermal growth factor receptor signaling in Her-2 negative breast cancer cells. Molecular and Cellular Biochemistry. 411: 221-33. PMID 26438086 DOI: 10.1007/S11010-015-2584-Y |
0.429 |
|
| 2016 |
Basha RM, Connelly SF, Purnachandra G, Sankpal UT, Patel H, Vishwanatha JK, Shelake S, Tabor-Simecka L, Shoji M, Simecka JSW, El-Rayes B. Abstract 4818: Tolfenamic acid and curcumin treatment induces pancreatic cancer cell growth inhibition via suppressing Sp1 expression, NF-kB translocation to nucleus Cancer Research. 76: 4818-4818. DOI: 10.1158/1538-7445.Am2016-4818 |
0.383 |
|
| 2016 |
Gibbs LD, Vishwanatha JK. Abstract 1426: Racial variation in annexin A2(AnxA2) gene expression and poor outcome in triple-negative breast cancer Cancer Research. 76: 1426-1426. DOI: 10.1158/1538-7445.Am2016-1426 |
0.367 |
|
| 2016 |
Gdowski A, Ranjan A, Mukerjee A, Sarker M, Kimbell J, Vishwanatha J. MP84-11 BONE MICROENVIRONMENT TARGETED NANOPARTICLES FOR METASTATIC PROSTATE CANCER TREATMENT Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2235 |
0.375 |
|
| 2016 |
Shetty P, Bargale A, Patil BR, Mohan R, Dinesh US, Vishwanatha JK, Gai PB, Patil VS, Amsavardani TS. Cell surface interaction of annexin A2 and galectin-3 modulates epidermal growth factor receptor signaling in Her-2 negative breast cancer cells Molecular and Cellular Biochemistry. 411: 221-233. DOI: 10.1007/s11010-015-2584-y |
0.317 |
|
| 2015 |
Shelake S, Eslin D, Sutphin RM, Sankpal UT, Wadwani A, Kenyon LE, Tabor-Simecka L, Bowman WP, Vishwanatha JK, Basha R. Combination of 13 cis-retinoic acid and tolfenamic acid induces apoptosis and effectively inhibits high-risk neuroblastoma cell proliferation. International Journal of Developmental Neuroscience : the Official Journal of the International Society For Developmental Neuroscience. 46: 92-9. PMID 26287661 DOI: 10.1016/J.Ijdevneu.2015.07.012 |
0.312 |
|
| 2015 |
Kpetemey M, Dasgupta S, Rajendiran S, Das S, Gibbs LD, Shetty P, Gryczynski Z, Vishwanatha JK. MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression. Molecular Cancer. 14: 156. PMID 26272794 DOI: 10.1186/S12943-015-0428-8 |
0.719 |
|
| 2015 |
Kokate RA, Thamake SI, Chaudhary P, Mott B, Raut SL, Vishwanatha JK, Jones H. Erratum: Enhancement of anti-tumor effect of particulate vaccine delivery system by 'Bacteriomimetic' (Nanomedicine (2015) 10:6 (915-929)) Nanomedicine: Nanotechnology, Biology and Medicine. 10. PMID 26008199 DOI: 10.2217/Nnm.15.55 |
0.696 |
|
| 2015 |
Rajendiran S, Kpetemey M, Maji S, Gibbs LD, Dasgupta S, Mantsch R, Hare RJ, Vishwanatha JK. MIEN1 promotes oral cancer progression and implicates poor overall survival. Cancer Biology & Therapy. 16: 876-85. PMID 25996585 DOI: 10.1080/15384047.2015.1040962 |
0.731 |
|
| 2015 |
Mukerjee A, Iyidogan P, Castellanos-Gonzalez A, Cisneros JA, Czyzyk D, Ranjan AP, Jorgensen WL, White AC, Vishwanatha JK, Anderson KS. A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium. Bioorganic & Medicinal Chemistry Letters. 25: 2065-7. PMID 25900220 DOI: 10.1016/J.Bmcl.2015.03.091 |
0.334 |
|
| 2015 |
Kokate RA, Thamake SI, Chaudhary P, Mott B, Raut S, Vishwanatha JK, Jones HP. Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles. Nanomedicine (London, England). 10: 915-29. PMID 25867857 DOI: 10.2217/Nnm.14.144 |
0.728 |
|
| 2015 |
Gdowski A, Ranjan A, Mukerjee A, Vishwanatha J. Development of biodegradable nanocarriers loaded with a monoclonal antibody. International Journal of Molecular Sciences. 16: 3990-5. PMID 25690029 DOI: 10.3390/Ijms16023990 |
0.353 |
|
| 2015 |
Griner NB, Young D, Chaudhary P, Mohamed AA, Huang W, Chen Y, Sreenath T, Dobi A, Petrovics G, Vishwanatha JK, Sesterhenn IA, Srivastava S, Tan SH. ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer. Molecular Cancer Research : McR. 13: 368-79. PMID 25344575 DOI: 10.1158/1541-7786.Mcr-14-0275-T |
0.39 |
|
| 2015 |
Chaudhary P, Vishwanatha JK. C-Jun NH<inf>2</inf>-terminal kinase-induced proteasomal degradation of c-FLIP<inf>L/S</inf> and Bcl<inf>2</inf> sensitize prostate cancer cells to Fas- and mitochondria-mediated apoptosis by tetrandrine Biochemical Pharmacology. 91: 457-473. PMID 25181458 DOI: 10.1016/J.Bcp.2014.08.014 |
0.376 |
|
| 2015 |
Kpetemey M, Dasgupta S, Rajendiran S, Das S, Gibbs LD, Shetty P, Gryczynski Z, Vishwanatha JK. MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression Molecular Cancer. 14. DOI: 10.1186/s12943-015-0428-8 |
0.683 |
|
| 2015 |
Maji S, Leitch AM, Akopova I, Nguyen P, Vishwanatha JK. Abstract B26: Role of exosomal annexin a2 in angiogenesis and breast cancer metastasis Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Tumang15-B26 |
0.423 |
|
| 2015 |
Kpetemey M, Vishwanatha J. Abstract 520: MIEN1 drives breast cancer invasion by regulating cytoskeletal dynamics Cancer Research. 75: 520-520. DOI: 10.1158/1538-7445.Am2015-520 |
0.352 |
|
| 2015 |
Gdowski A, Ranjan A, Mukerjee A, Vishwanatha J. Abstract 4396: Nanocarrier for monoclonal antibody delivery Cancer Research. 75: 4396-4396. DOI: 10.1158/1538-7445.Am2015-4396 |
0.338 |
|
| 2015 |
Chaudhary P, Gibbs LD, Vishwanatha JK. Abstract 1677: Annexin A2 antibody inhibits the progression of triple-negative and herceptin-resistant breast cancer by blocking epidermal growth factor receptor functions Cancer Research. 75: 1677-1677. DOI: 10.1158/1538-7445.Am2015-1677 |
0.431 |
|
| 2014 |
Rajendiran S, Parwani AV, Hare RJ, Dasgupta S, Roby RK, Vishwanatha JK. MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1. Molecular Cancer. 13: 250. PMID 25406943 DOI: 10.1186/1476-4598-13-250 |
0.723 |
|
| 2014 |
Chaudhary P, Thamake SI, Shetty P, Vishwanatha JK. Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies British Journal of Cancer. 111: 2328-2341. PMID 25321192 DOI: 10.1038/Bjc.2014.542 |
0.753 |
|
| 2014 |
Gdowski A, Ranjan AP, Mukerjee A, Vishwanatha JK. Nanobiosensors: role in cancer detection and diagnosis. Advances in Experimental Medicine and Biology. 807: 33-58. PMID 24619617 DOI: 10.1007/978-81-322-1777-0_4 |
0.355 |
|
| 2014 |
Mukerjee A, Ranjan AP, Vishwanatha JK, Helson L. Non-covalent surface integration: Optimizing a novel technique for preparing targeted polymeric nanoparticles for cancer therapeutics International Journal of Nanotechnology. 11: 676-685. DOI: 10.1504/Ijnt.2014.060590 |
0.406 |
|
| 2014 |
Ranjan AP, Mukerjee A, Vishwanatha JK. Abstract 4472: Targeted multifunctional lipid-PLGA hybrid nanosystems for metastatic breast cancer imaging and therapy Cancer Research. 74: 4472-4472. DOI: 10.1158/1538-7445.Am2014-4472 |
0.421 |
|
| 2013 |
Chaudhary P, Sharma R, Sahu M, Vishwanatha JK, Awasthi S, Awasthi YC. 4-Hydroxynonenal induces G2/M phase cell cycle arrest by activation of the ataxia telangiectasia mutated and Rad3-related protein (ATR)/checkpoint kinase 1 (Chk1) signaling pathway. The Journal of Biological Chemistry. 288: 20532-46. PMID 23733185 DOI: 10.1074/Jbc.M113.467662 |
0.318 |
|
| 2013 |
Chaudhary P, Vishwanatha JK. Abstract A052: Inhibition of triple-negative and Her-2 resistant breast cancer proliferation and migration by Annexin A2 antibodies Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A052 |
0.44 |
|
| 2013 |
Rajendiran S, Vishwanatha JK. Abstract 5345: MicroRNA mediated regulation of a novel gene, MIEN1, in cancer metastasis. Cancer Research. 73: 5345-5345. DOI: 10.1158/1538-7445.Am2013-5345 |
0.441 |
|
| 2013 |
Kokate R, Thamake S, Jones H, Vishwanatha J, Mott B. Abstract 1270: Mimicking infection for immunotherapy against breast cancer - fooling the immune system. Cancer Research. 73: 1270-1270. DOI: 10.1158/1538-7445.Am2013-1270 |
0.734 |
|
| 2013 |
Mott B, Thamake S, Vishwanatha J, Jones HP. Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae Journal of Nanoparticle Research. 15. DOI: 10.1007/S11051-013-1646-X |
0.706 |
|
| 2012 |
Kpetemey M, Kashyap MV, Gibbs L, Vishwanatha JK. Breast cancer disparities: Frontline strategies, proceedings of the 7(th) annual texas conference on health disparities. Journal of Carcinogenesis. 11: 16. PMID 23230393 DOI: 10.4103/1477-3163.102950 |
0.324 |
|
| 2012 |
Shetty PK, Thamake SI, Biswas S, Johansson SL, Vishwanatha JK. Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer. Plos One. 7: e44299. PMID 22957061 DOI: 10.1371/Journal.Pone.0044299 |
0.75 |
|
| 2012 |
Ondricek AJ, Kashyap AK, Thamake SI, Vishwanatha JK. A comparative study of phytoestrogen action in mitigating apoptosis induced by oxidative stress. In Vivo (Athens, Greece). 26: 765-75. PMID 22949589 |
0.689 |
|
| 2012 |
Ranjan AP, Mukerjee A, Helson L, Vishwanatha JK. Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. Journal of Nanobiotechnology. 10: 38. PMID 22937885 DOI: 10.1186/1477-3155-10-38 |
0.313 |
|
| 2012 |
Thamake SI, Raut SL, Gryczynski Z, Ranjan AP, Vishwanatha JK. Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials. 33: 7164-73. PMID 22795543 DOI: 10.1016/J.Biomaterials.2012.06.026 |
0.737 |
|
| 2012 |
Mukerjee A, Ranjan AP, Vishwanatha JK. Combinatorial nanoparticles for cancer diagnosis and therapy. Current Medicinal Chemistry. 19: 3714-21. PMID 22680922 DOI: 10.2174/092986712801661176 |
0.333 |
|
| 2012 |
Dasgupta S, Srinidhi S, Vishwanatha JK. Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges. Journal of Carcinogenesis. 11: 4. PMID 22438770 DOI: 10.4103/1477-3163.93001 |
0.723 |
|
| 2012 |
Shetty PK, Thamake SI, Biswas S, Johansson SL, Vishwanatha JK. Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer Plos One. 7. DOI: 10.1371/annotation/ba62ae01-bf71-46c1-a45c-32692d3bb4ab |
0.713 |
|
| 2011 |
Mukerjee A, Shankardas J, Ranjan AP, Vishwanatha JK. Efficient nanoparticle mediated sustained RNA interference in human primary endothelial cells. Nanotechnology. 22: 445101. PMID 21990205 DOI: 10.1088/0957-4484/22/44/445101 |
0.395 |
|
| 2011 |
Ranjan AP, Zeglam K, Mukerjee A, Thamake S, Vishwanatha JK. A sustained release formulation of chitosan modified PLCL:poloxamer blend nanoparticles loaded with optical agent for animal imaging. Nanotechnology. 22: 295104. PMID 21693801 DOI: 10.1088/0957-4484/22/29/295104 |
0.716 |
|
| 2011 |
Dasgupta S, Cushman I, Kpetemey M, Casey PJ, Vishwanatha JK. Prenylated c17orf37 induces filopodia formation to promote cell migration and metastasis. The Journal of Biological Chemistry. 286: 25935-46. PMID 21628459 DOI: 10.1074/Jbc.M111.254599 |
0.715 |
|
| 2011 |
Valapala M, Thamake SI, Vishwanatha JK. A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events. Journal of Cell Science. 124: 1453-64. PMID 21486955 DOI: 10.1242/Jcs.079236 |
0.708 |
|
| 2011 |
Thamake SI, Raut SL, Ranjan AP, Gryczynski Z, Vishwanatha JK. Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy. Nanotechnology. 22: 035101. PMID 21149963 DOI: 10.1088/0957-4484/22/3/035101 |
0.738 |
|
| 2010 |
Das S, Shetty P, Valapala M, Dasgupta S, Gryczynski Z, Vishwanatha JK. Signal transducer and activator of transcription 6 (STAT6) is a novel interactor of annexin A2 in prostate cancer cells. Biochemistry. 49: 2216-26. PMID 20121258 DOI: 10.1021/Bi9013038 |
0.716 |
|
| 2010 |
Zhang FF, John EM, West DW, Knight J, Andrulis I, Buys S, Daly M, Stearman B, Kaur M, Vishwanatha J, Morabia A, Terry MB. Abstract 2830: Energy balance and breast cancer risk among sisters pairs in the Breast Cancer Family Registry Study Cancer Research. 70: 2830-2830. DOI: 10.1158/1538-7445.Am10-2830 |
0.329 |
|
| 2010 |
Cardarelli KM, Haley S, Linnear K, Jackson R, Martin M, Lopez R, Senteio C, Weaver P, Hill A, Banda J, Epperson-Brown M, Morrison J, Parrish D, Newton J, Royster M, ... ... Vishwanatha JK, et al. Abstract B2: Educational intervention to reduce breast cancer disparities: The Dallas Cancer Disparities Community Research Coalition Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-B2 |
0.323 |
|
| 2009 |
Dasgupta S, Wasson LM, Rauniyar N, Prokai L, Borejdo J, Vishwanatha JK. Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. Oncogene. 28: 2860-72. PMID 19503095 DOI: 10.1038/Onc.2009.145 |
0.741 |
|
| 2009 |
Braden AR, Kafka MT, Cunningham L, Jones H, Vishwanatha JK. Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth. Journal of Nanoscience and Nanotechnology. 9: 2856-65. PMID 19452941 DOI: 10.1166/Jnn.2009.028 |
0.419 |
|
| 2009 |
Dasgupta S, Vishwanatha JK. Abstract A9: Importance of C17orf37 prenyl modification in cancer cell migration and invasion Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-A9 |
0.718 |
|
| 2008 |
Bhutia SK, Mallick SK, Stevens SM, Prokai L, Vishwanatha JK, Maiti TK. Induction of mitochondria-dependent apoptosis by Abrus agglutinin derived peptides in human cervical cancer cell. Toxicology in Vitro : An International Journal Published in Association With Bibra. 22: 344-51. PMID 18024076 DOI: 10.1016/J.Tiv.2007.09.016 |
0.305 |
|
| 2007 |
Das S, Roth CP, Wasson LM, Vishwanatha JK. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. The Prostate. 67: 1550-64. PMID 17705178 DOI: 10.1002/Pros.20640 |
0.361 |
|
| 2007 |
Braden A, Kashyap A, Vasir J, Labhasetwar V, Vishwanatha JK. Polymeric nanoparticles for sustained down-regulation of annexin A2 lead to reduction in proliferation and migration of prostate cancer cells Journal of Biomedical Nanotechnology. 3: 148-159. DOI: 10.1166/Jbn.2007.010 |
0.453 |
|
| 2007 |
Dasgupta S, Vishwanatha JK. Role of C17orf37/MGC14832 in prostate cancer cell proliferation and migration The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A289-B |
0.717 |
|
| 2005 |
Banerjee AG, Bhattacharyya I, Vishwanatha JK. Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia. Molecular Cancer Therapeutics. 4: 865-75. PMID 15956244 DOI: 10.1158/1535-7163.Mct-05-0033 |
0.322 |
|
| 2005 |
Rothermund CA, Gopalakrishnan VK, Eudy JD, Vishwanatha JK. Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. Bmc Urology. 5: 5. PMID 15790403 DOI: 10.1016/S1569-9056(03)80862-X |
0.35 |
|
| 2004 |
Rothermund CA, Gopalakrishnan VK, Vishwanatha JK. Androgen signaling and post-transcriptional downregulation of Bcl-2 in androgen-unresponsive prostate cancer. Prostate Cancer and Prostatic Diseases. 7: 158-64. PMID 15124003 DOI: 10.1038/Sj.Pcan.4500717 |
0.374 |
|
| 2004 |
Vishwanatha JK, Salazar E, Gopalakrishnan VK. Absence of annexin I expression in B-cell non-Hodgkin's lymphomas and cell lines. Bmc Cancer. 4: 8. PMID 15070421 DOI: 10.17925/Ohr.2005.00.00.1G |
0.411 |
|
| 2004 |
Vishwanatha J, Banerjee A, Liu J, Gopalakrishnan V. 456 Biomarkers modulating angiogenesis in prostate cancers from USA and India European Urology Supplements. 3: 116. DOI: 10.1016/S1569-9056(04)90453-8 |
0.348 |
|
| 2003 |
Banerjee AG, Liu J, Yuan Y, Gopalakrishnan VK, Johansson SL, Dinda AK, Gupta NP, Trevino L, Vishwanatha JK. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA. Molecular Cancer. 2: 34. PMID 14613585 DOI: 10.1186/1476-4598-2-34 |
0.348 |
|
| 2003 |
Liu J, Rothermund CA, Ayala-Sanmartin J, Vishwanatha JK. Nuclear annexin II negatively regulates growth of LNCaP cells and substitution of ser 11 and 25 to glu prevents nucleo-cytoplasmic shuttling of annexin II. Bmc Biochemistry. 4: 10. PMID 12962548 DOI: 10.1186/1471-2091-4-10 |
0.358 |
|
| 2003 |
Gopalakrishnan VK, Banerjee AG, Vishwanatha JK. Effect of FHIT gene replacement on growth, cell cycle and apoptosis in pancreatic cancer cells. Pancreatology : Official Journal of the International Association of Pancreatology (Iap) ... [Et Al.]. 3: 293-302. PMID 12890991 DOI: 10.1159/000071767 |
0.4 |
|
| 2003 |
Vishwanatha JK, Swinney R, Banerjee AG. Modulation of annexin I and cyclooxygenase-2 in smokeless tobacco-induced inflammation and oral cancer. Molecular and Cellular Biochemistry. 248: 67-75. PMID 12870656 DOI: 10.1023/A:1024153431272 |
0.352 |
|
| 2000 |
Guo Z, Johansson SL, Rhim JS, Vishwanatha JK. Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model. The Prostate. 43: 101-10. PMID 10754525 DOI: 10.1002/(Sici)1097-0045(20000501)43:2<101::Aid-Pros4>3.0.Co;2-A |
0.413 |
|
| 2000 |
Guo Z, Vishwanatha JK. Effect of regulated expression of the fragile histidine triad gene on cell cycle and proliferation. Molecular and Cellular Biochemistry. 204: 83-8. PMID 10718628 DOI: 10.1023/A:1007068823848 |
0.347 |
|
| 1999 |
Mangipudy RS, Vishwanatha JK. Role of nitric oxide in the induction of apoptosis by smokeless tobacco extract. Molecular and Cellular Biochemistry. 200: 51-7. PMID 10569183 DOI: 10.1023/A:1006985700851 |
0.305 |
|
| 1999 |
Chiang Y, Rizzino A, Sibenaller ZA, Wold MS, Vishwanatha JK. Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Molecular and Cellular Biochemistry. 199: 139-47. PMID 10544962 DOI: 10.1023/A:1006942128672 |
0.338 |
|
| 1993 |
Vishwanatha JK, Chiang Y, Kumble KD, Hollingsworth MA, Pour PM. Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers Carcinogenesis. 14: 2575-2579. PMID 8269629 DOI: 10.1093/Carcin/14.12.2575 |
0.353 |
|
| Show low-probability matches. |